Update on Aromatase Inhibitors

Brent O'Carrigan, Matthew HF Wong, Melina L Willson, Martin R Stockler, Nick Pavlakis, Annabel Goodwin, Bisphosphonates and other bone agents for breast cancer. Cochrane Database of Systematic Reviews. ,vol. 10, pp. 0- 0 ,(2017) , 10.1002/14651858.CD003474.PUB4

Niamh McGrath, Michael J O'Grady, Aromatase inhibitors for short stature in male children and adolescents Cochrane Database of Systematic Reviews. ,(2015) , 10.1002/14651858.CD010888.PUB2

Daniela Bosco, Osteoporosis and aromatase inhibitors: experience and future prospects. Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases. ,vol. 9, pp. 89- 91 ,(2012)

Huan Song, DongHao Lu, Kate Navaratnam, Gang Shi, Aromatase inhibitors for uterine fibroids Cochrane Database of Systematic Reviews. ,(2013) , 10.1002/14651858.CD009505.PUB2

Ashraf A ElDaly, Haya Al-Fozan, Hesham G Al-Inany, Mohamed A Bedaiwy, Wael Fayek Saleh, Aromatase inhibitors for ovulation induction Cochrane Database of Systematic Reviews. ,(2015) , 10.1002/14651858.CD005635.PUB2

Lorna Gibson, David Lawrence, Claire Dawson, Judith Bliss, Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women Cochrane Database of Systematic Reviews. ,vol. 2007, pp. 003370- ,(2009) , 10.1002/14651858.CD003370.PUB3

John FR Robertson, Jean-Marc Ferrero, Hugues Bourgeois, Hagen Kennecke, Richard H de Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, Jennifer L Gansert, Peter A Kaufman, Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind, phase 2 trial Lancet Oncology. ,vol. 14, pp. 228- 235 ,(2013) , 10.1016/S1470-2045(13)70026-3

O. Ortmann, O. Pagani, A. Jones, N. Maass, D. Noss, H. Rugo, C. van de Velde, Matti Aapro, R. Coleman, Which factors should be taken into account in perimenopausal women with early breast cancer who may become eligible for an aromatase inhibitor? Recommendations of an expert panel. Cancer Treatment Reviews. ,vol. 37, pp. 97- 104 ,(2011) , 10.1016/J.CTRV.2010.05.005

Thomas Kolben, Susanne Engelmann, Susanne Maurer, Martin Kolben, Use of Adjuvant Endocrine Therapy in Postmenopausal Hormone Receptor-Positive Breast Cancer at German Breast Cancer Centers and University Hospitals - Results of an Enquiry (Adjuvant Endocrine Therapy Enquiry). Breast Care. ,vol. 7, pp. 39- 44 ,(2012) , 10.1159/000336531

ROBERT F. CASPER, MOHAMED F.M. MITWALLY, Use of the aromatase inhibitor letrozole for ovulation induction in women with polycystic ovarian syndrome. Clinical Obstetrics and Gynecology. ,vol. 54, pp. 685- 695 ,(2011) , 10.1097/GRF.0B013E3182353D0F